[8] It was approved for medical use in the United States in 2018,[8] the European Union in 2019,[7] the UK in 2020[4] and Argentina by September 2021.

[10] The most common adverse effects are reactions at the injection site, which occurred in 43 to 45% of people in studies (as compared to 38% under placebo).

[6] Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptides (CGRP) alpha and beta.

Like other proteins, the substance is degraded by proteolysis to small peptides and amino acids, which are reused or excreted via the kidney.

[11] Fremanezumab was discovered and developed by Rinat Neuroscience, was acquired by Pfizer in 2006, and was then licensed to Teva.